Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

NCT00686517 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

BIOLOGICAL: Pegylated interferon alfa-2b
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]